Cart
sales@molnova.com
IHMT-PI3Kδ-372 S-isomer
CAS No. 2429889-61-0
IHMT-PI3Kδ-372 S-isomer( —— )
Catalog No. M35371 CAS No. 2429889-61-0
IHMT-PI3Kδ-372 S-isomer is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 S-isomer shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 311 | In Stock |
|
| 2MG | 166 | In Stock |
|
| 5MG | 255 | In Stock |
|
| 10MG | 374 | In Stock |
|
| 25MG | 562 | In Stock |
|
| 50MG | 770 | In Stock |
|
| 100MG | 1051 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIHMT-PI3Kδ-372 S-isomer
-
NoteResearch use only, not for human use.
-
Brief DescriptionIHMT-PI3Kδ-372 S-isomer is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 S-isomer shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases.
-
DescriptionIHMT-PI3Kδ-372 S-isomer is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 S-isomer shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2429889-61-0
-
Formula Weight503.5
-
Molecular FormulaC26H23F2N7O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@@H](CC)(N1C=2C(C(=N1)C3=CC(F)=C(OC)C=C3)=C(N)N=CN2)C=4N(C(=O)C=5C(N4)=CC=CC5F)C6CC6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
IHMT-PI3Kδ-372
IHMT-PI3Kδ-372 is a selective inhibitor of PI3Kδ with an IC50 of 14 nM and can be used in studies about chronic obstructive pulmonary disease.
-
GSK251
GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of PI3Kδ with a novel binding mode.
-
SF2523
A novel potent, dual inhibitor of PI3K and BRD4 with IC50 of 241, 34, 158 nM for BRD4 (BD1), PI3Kα and PI3Kγ, respectively.
